27 / 154
Contents
xxvii
OUTCOMEANDAGE DEPENDENT DIFFERENCES IN CHOICE OFADJUVANT CHEMOTHERAPY IN PATIENTS
WITH PRIMARY COLORECTAL CANCER (THE ACCORE STUDY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S41
A PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE USE OF BEVACIZUMAB AND CONVENTIONAL
CHEMOTHERAPY FOR FIRST LINE ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER
(MCRC): TREATMENT DURATION AND TOXICITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S41
RETROSPECTIVE STUDY OF FRENCH PHYSICIANS’ PRACTICES IN CAPECITABINE PRESCRIPTION FOR
OLDER PATIENTS WITH METASTATIC FIRST LINE BREAST CANCER (CAPAGE STUDY) . . . . . . . . . . . . . . . . . .S42
ASTER 70S OR OPTIMAL ADJUVANT TREATMENT FOR WOMEN OVER 70 WITH LUMINAL BREAST
CANCER: A GERICO/UNICANCER PHASE III TRIAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S42
FUNCTIONAL AND COGNITIVE IMPAIRMENT, SOCIAL ENVIRONMENT, FRAILTY AND ADVERSE HEALTH
OUTCOMES IN OLDER PATIENTS WITH HEAD AND NECK CANCER, A SYSTEMATIC REVIEW . . . . . . . . . . . .S43
DESCRIPTIVE EPIDEMIOLOGICAL STUDY OF GERIATRIC CANCER SEEN IN TATA MEMORIAL HOSPITAL,
MUMBAI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S44
COMBINATION CHEMOTHERAPY WITH DOCETAXEL AND CARBOPLATIN FOR ELDERLY PATIENTS WITH
ENDOMETRIAL CANCER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S44
LONGSURVIVALOFAMETASTATICBREASTCANCERSERIESOF ELDERLYPATIENTS INACOMPREHENSIVE
CANCER CENTER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S45
IL-6 SECRETION REDUCTION IN ELDERLY PATIENTS UNDERGOING ELECTIVE COLORECTAL
LAPAROSCOPIC SURGERY UNDER ERAS. RESULTS FROM A RANDOMIZED CLINICAL TRIAL. . . . . . . . . . . . . .S45
OCTOGENARIANS WITH INOPERABLE MALIGNANT PLEURAL MESOTHELIOMA: OUTCOME OF
CARBOPLATIN AND PEMETREXED CHEMOTHERAPY. A SIX YEARS CONSECUTIVE COHORT . . . . . . . . . . . . .S46
MULTIDISCIPLINARY DECISION-MAKING IN LUNG CANCER PATIENTS: AN AGED BASED COMPARISON. . . . .S46
POSTOPERATIVECOMPLICATIONSANDMORTALITY IN INDIVIDUALSAGED70ANDOLDERUNDERGOING
SURGERY FOR COLORECTAL CANCER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S47
EFFICACY AND SAFETY OF ANTIANGIOGENIC THERAPIES IN ELDERLY PATIENTS WITH METASTATIC
RENAL CELL CARCINOMA: A RETROSPECTIVE MULTICENTER STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S47
TOLERANCEANDEFFICACYOF FOLFIRINOX INELDERLY PATIENTSWITHPANCREACTICORCOLORECTAL
CANCER. A MONOCENTRIC RETROSPECTIVE STUDY ON 52 PATIENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S48
GERIATRIC ASSESSMENT AND FUNCTIONAL DECLINE IN OLDER PATIENTS WITH LUNG CANCER. . . . . . . . . .S49
UTILITY OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS WITH LOCALLY ADVANCED LUNG CANCER
TO BE TREATEDWITH CONCURRENT CHEMORADIATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S49
CLUSTERING ANALYSIS OF OESTROGEN RECEPTOR POSITIVE EARLY OPERABLE PRIMARY BREAST
CANCER IN OLDER WOMEN – A STUDY BASED ON CORE NEEDLE BIOPSY . . . . . . . . . . . . . . . . . . . . . . . . . . . .S50
FINAL RESULTS OF GERICO 10 GETUG P03 TRIAL EVALUATING FEASIBILITY OF DOCETAXEL IN
VULNERABLE OR FRAIL ELDERLY (75+) PATIENTS WITH METASTATIC CASTRATION RESISTANT
PROSTATE CANCER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S51
UNRESECTABLE AND METASTATIC PANCREATIC ADENOCARCINOMA IN THE ELDERLY: A 10-YEAR
SINGLE-CENTER EXPERIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S51
THE IMPACT OF AN OSTOMY ON OLDER COLORECTAL CANCER PATIENTS: A CROSS-SECTIONAL SURVEY . .S52
HCC ASSOCIATED WITH HIGHEST INPATIENT POST-OPERATIVE MORTALITY AMONGST GI CANCERS:
ELDERLY AGE HIGHEST PREDICTIVE RISK FACTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S53
RETROSPECTIVE CORELATION OF BIOPSY WITH PSA SCREENING VALUES OF GERIATRIC INDIVIDUALS
IN A TERTIARY CARE TEACHING HOSPITAL IN INDIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S53
A PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB WITH CYTOTOXIC CHEMOTHERAPY,
AS FIRST LINE TREATMENT, IN OLDER PATIENTS WITH ADVANCED/METASTATIC NSCLC (NON-
SQUAMOUS) SELECTED BY A GERIATRIC ASSESSMENT: GIDO1201 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S54
ARE OLDER PATIENTS PROPERLY REPRESENTED IN CLINICAL TRIALS? ANALYSIS OF THE SCREENING
FAILURES REASONS IN ELDERLY NON-SMALL CELL LUNG CANCER PATIENTS (NSCLC) STAGE IV
ASSESSED FOR BEVACIZUMAB THERAPY (GIDO1201 TRIAL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S55
SHORT-TERM CHANGES IN MOOD AS MEASURED BY COMPREHENSIVE GERIATRIC ASSESSMENT (CGA)
SCORES FOLLOWING TREATMENT OF PRIMARY BREAST CANCER IN OLDER WOMEN . . . . . . . . . . . . . . . . . .S55
ANDROGEN DEPRIVATIONTHERAPY ANDTHE RISK OF PARKINSONISM IN OLDER MENWITH PROSTATE
CANCER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S56
CLINICAL AND TREATMENT FACTORS ASSOCIATED WITH SURVIVAL AMONG WOMEN 70 YEARS AND
OLDER WITH EPITHELIAL OVARIAN CANCER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S56
SAFETY AND EFFICACY OF LOWER DOSE WEEKLY TOPOTECAN IN ELDERLY PATIENTS WITH PLATINUM
RESISTANT OVARIAN AND PERITONEAL CANCER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S57
DOWE KNOWWHAT OLDERWOMENWITH BREAST CANCERWANT? DECISION MAKING PREFERENCES
FOR TYPE OF TREATMENT, FOLLOW UP AND PERCEPTIONS OF COSMETIC OUTCOMES. . . . . . . . . . . . . . . . .S57
ASSOCIATION OF PRE-CHEMOTHERAPY PERIPHERAL BLOOD BIOMARKERS OF AGING (IL-6, CRP AND
D-DIMER) WITH CHEMOTHERAPYTOXICITY AND RELATIVE DOSE INTENSITY (RDI) INWOMENWITH
BREAST CANCER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S58
DIFFUSE LARGE B CELL LYMPHOMA: AN OVERVIEW OF THE DISEASE WITH SPECIAL FOCUS ON CIRS
SCALE AND EMERGENCY VISITS IN THE ELDERLY POPULATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S59